MedWatch

Democrats want insulin producers investigated

Insulin producers Novo Nordisk, Sanofi and Eli Lilly have come under attack from Democratic Party representatives in the US who have encouraged the US Federal Trade Commission to investigate them for potential collusion in the US insulin market.

Representative Katie Porter | Photo: Erin Scott/Reuters/Ritzau Scanpix

Six prominent members of the US House of Representatives including Katie Porter, who has previously been committed to regulating the pharmaceutical industry, have sent a letter to the US Federal Trade Commission (FTC) encouraging this authority to investigate Novo Nordisk, Sanofi and Eli Lilly, according to media Endpoints News.

In the letter, the six Democrats detail that the firms raised their insulin prices at the same time, which caused the price to nearly double between 2012 and 2016. For this reason, it should be investigated whether the involved parties had agreed on this in advance, the Democrats state.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Latest news

See all jobs